Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.
about
Versatile virus-like particle carrier for epitope based vaccinesEnhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine.Isolation of human monoclonal antibodies by mammalian cell display.Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistryCardiorespiratory anomalies in mice lacking CB1 cannabinoid receptors.Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trialRoles of inflammation, oxidative stress, and vascular dysfunction in hypertension.Hypertension Vaccine may be a boon to millions in developing world.Vaccines in the management of hypertension.Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis.A cholesterol-lowering VLP vaccine that targets PCSK9Bacterial superglue enables easy development of efficient virus-like particle based vaccines.Construction, expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle.Bacterially produced recombinant influenza vaccines based on virus-like particles.Vaccines and global health.Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations.Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platformModulation of anti-tumor necrosis factor alpha (TNF-α) antibody secretion in mice immunized with TNF-α kinoidVaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathyInhibition of neointima formation through DNA vaccination for apolipoprotein(a): a new therapeutic strategy for lipoprotein(a)Engineering virus-like particles as vaccine platformsEmerging applications of anticytokine vaccines.Targeted immunomodulation using antigen-conjugated nanoparticles.Update on newer antihypertensive medicines and interventions.Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines.Virus-like particles in vaccine development.Therapeutic vaccines for chronic diseases: successes and technical challenges.Emerging drugs which target the renin-angiotensin-aldosterone system.Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.Preventive aspects in peripheral artery disease.Are there any new pharmacologic therapies on the horizon to better treat hypertension? A state-of-the-art paper.Decade in review--hypertension: the past decade in hypertension--facts, hopes, and hypes.Novel RAAS agonists and antagonists: clinical applications and controversies.Development of DNA vaccines as an anti-hypertensive therapy or for anti-angiogenesis.Drug therapy for the patient with resistant hypertension.Bioengineering strategies to generate artificial protein complexes.Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments.Peptide Vaccines for Hypertension and Diabetes Mellitus.The application of virus-like particles as vaccines and biological vehicles.
P2860
Q28748358-1BAE9602-68CE-48C2-A8AC-2FA0F0E31070Q30355360-2C2CB766-201D-4427-9934-FEDD431F65F0Q33371477-D78151B7-BFEB-411B-9D57-D3F5A8618CDAQ33707408-FD5CF6A9-311D-4637-ACF3-002CAED215A6Q33784193-C0B81915-EF06-46E2-8B80-5A9AD0138146Q33883669-7FEDE104-C486-4668-9F7D-9C7EC7ED861AQ34013918-A6B78A6B-FBB5-43EF-B499-E4B6EC670173Q34033817-4D39984B-1D70-4DFB-A26C-BC891A41BBB1Q34114402-25FC70FA-1DB8-435B-B09E-ABAD22EEBB42Q34413235-FAB9FE72-23CB-4905-8E11-EA94AF69F38CQ34496015-622B1963-7AC3-4C2E-B7A2-8D5D64AFB8C2Q34523734-8937C5CC-9BCF-4606-AC23-86C9AF068220Q34587965-7D4385E8-629D-484E-96D8-2FBC5C09007DQ35048127-E2245EF2-A8E5-49E6-A7CD-A235F7DCD496Q35137116-B4E57987-6B15-4B5B-9979-6CE5FF554637Q35156759-D66ECCC6-CA9A-4BCD-80DC-0D075800FCC7Q35231679-9D2D3F6C-69F6-4768-9447-CDCBBAA87615Q35591551-931BC800-FDDC-41FE-BEEA-FCDB1B1F8A58Q35940690-85E9E1BE-51BC-4C01-99CA-067CCA62DBF7Q36605186-4500B079-0AEF-4699-AF6D-D3D60924E326Q36736883-E5062713-861E-4BB6-B776-7F257B2DD827Q37172342-E58CC1FB-45D6-498F-9205-7462B11BABB4Q37340457-6B51AC9E-D5ED-4F0A-AFF4-924E2C23CBD4Q37705215-0DCD8A7A-A1BA-4B3D-B959-D339A65CE6C4Q37753547-04400345-B6ED-4B08-BAA8-576A267BCD0CQ37773295-32AAD2E8-8983-479D-AB11-3B7976F4D1ADQ37798008-20228DA8-ACD4-4F39-B051-F916E2D3BC10Q37926764-05AA546F-C3B8-4190-B4D6-FB8979C7F222Q37929786-604737A3-FB7D-433B-8AA5-F9FD1C9DE31EQ37939427-D48DD002-993D-4DBC-95F0-0F94EA2BEF97Q37984281-6C5F00BD-1444-424A-828D-7FA3DF3A8CC3Q38208808-9A201670-5040-4CB8-9889-4F4608035860Q38245286-C6B3F9D1-4CAF-4189-96AD-75D5E6EBC416Q38349798-DF901484-3171-4A5C-9B10-9FE49FFDC9F6Q38352286-E70DBA79-B51B-489D-A833-F1397A2F7C48Q38373858-04D130A1-0CD5-4C22-9E89-2048D5B8E145Q38460874-724EF285-B366-4082-8155-740D11560A55Q38467270-4AD19682-4D3B-44F3-A8A2-B3DB7BA3913BQ38582135-372603BD-17C6-4F25-8B34-C816F6A7FBFDQ38603912-4951E1D7-11C7-4C5F-9F02-D7B0EE45AA67
P2860
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Effect of immunisation against ...... bo-controlled phase IIa study.
@ast
Effect of immunisation against ...... bo-controlled phase IIa study.
@en
Effect of immunisation against ...... bo-controlled phase IIa study.
@nl
type
label
Effect of immunisation against ...... bo-controlled phase IIa study.
@ast
Effect of immunisation against ...... bo-controlled phase IIa study.
@en
Effect of immunisation against ...... bo-controlled phase IIa study.
@nl
prefLabel
Effect of immunisation against ...... bo-controlled phase IIa study.
@ast
Effect of immunisation against ...... bo-controlled phase IIa study.
@en
Effect of immunisation against ...... bo-controlled phase IIa study.
@nl
P2093
P1433
P1476
Effect of immunisation against ...... bo-controlled phase IIa study.
@en
P2093
Alain C Tissot
Frank Wagner
Gary T Jennings
Hans Stocker
Hans-Dieter Volk
Juerg Nussberger
Martin F Bachmann
Patrik Maurer
Philipp Müller
Robert Sabat
P304
P356
10.1016/S0140-6736(08)60381-5
P407
P577
2008-03-01T00:00:00Z